[go: up one dir, main page]

TR200102802T2 - Tabletlerin direk kompresyonla üretiminde, yüksek L-karnitin-alkanoil L-karnitinli granülat - Google Patents

Tabletlerin direk kompresyonla üretiminde, yüksek L-karnitin-alkanoil L-karnitinli granülat

Info

Publication number
TR200102802T2
TR200102802T2 TR2001/02802T TR200102802T TR200102802T2 TR 200102802 T2 TR200102802 T2 TR 200102802T2 TR 2001/02802 T TR2001/02802 T TR 2001/02802T TR 200102802 T TR200102802 T TR 200102802T TR 200102802 T2 TR200102802 T2 TR 200102802T2
Authority
TR
Turkey
Prior art keywords
carnitine
granulate
direct compression
alkanoyl
tablets
Prior art date
Application number
TR2001/02802T
Other languages
English (en)
Inventor
Hassen Ken
Original Assignee
Biosint S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosint S.P.A. filed Critical Biosint S.P.A.
Publication of TR200102802T2 publication Critical patent/TR200102802T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Confectionery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Terapötik/nutrisyonel etki gösteren, granüllü/baglayici materyal ile kapli, yüksek aktif madde içerikli kati uygulama formuna çevirmek için uygun, özellikle direk kompresyon yöntemiyle elde edilen tablet formunda veya kapsül içeriginin olusturulmasi için uygun aktif madde granüllerini içeren bir granülat tanimlanmaktadir.
TR2001/02802T 1999-03-26 2000-03-22 Tabletlerin direk kompresyonla üretiminde, yüksek L-karnitin-alkanoil L-karnitinli granülat TR200102802T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999RM000189A IT1305308B1 (it) 1999-03-26 1999-03-26 Granulato ad alto contenuto di l-carnitina o alcanoil-l-carnitina,particolarmente adatto alla produzione di compresse per compressione

Publications (1)

Publication Number Publication Date
TR200102802T2 true TR200102802T2 (tr) 2002-04-22

Family

ID=11406608

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02802T TR200102802T2 (tr) 1999-03-26 2000-03-22 Tabletlerin direk kompresyonla üretiminde, yüksek L-karnitin-alkanoil L-karnitinli granülat

Country Status (20)

Country Link
US (1) US6485741B2 (tr)
EP (1) EP1171111B1 (tr)
JP (2) JP4637367B2 (tr)
KR (1) KR100729848B1 (tr)
CN (1) CN1158072C (tr)
AT (1) ATE238784T1 (tr)
AU (1) AU780413B2 (tr)
CA (1) CA2363038C (tr)
CZ (1) CZ301266B6 (tr)
DE (1) DE60002454T2 (tr)
DK (1) DK1171111T3 (tr)
ES (1) ES2197867T3 (tr)
HU (1) HU228588B1 (tr)
IL (2) IL144957A0 (tr)
IT (1) IT1305308B1 (tr)
PL (1) PL207961B1 (tr)
PT (1) PT1171111E (tr)
SK (1) SK285565B6 (tr)
TR (1) TR200102802T2 (tr)
WO (1) WO2000057873A2 (tr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017525A1 (en) * 1999-09-03 2001-03-15 Sigma-Tau Healthscuience S.P.A Ultrafine l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same
CN1686089B (zh) * 2005-05-08 2010-08-18 北京健健康康生物技术有限公司 一种可直接压片的木糖醇颗粒及其制备方法
ATE555774T1 (de) * 2005-07-05 2012-05-15 Lonza Ag Sprühtrockenverfahren zur herstellung eines trockenen carnitin-pulvers oder -granulats
MX342962B (es) * 2009-09-18 2016-06-07 Teva Pharmaceuticals Holdings Mexico S A De C V Composicion farmaceutica para bajar de peso y procedimiento para obtener la misma.
EP2335495A1 (en) 2009-12-11 2011-06-22 Lonza Ltd. Carnitine granulate and methods for its production
CN102349881B (zh) * 2011-10-26 2013-06-26 东北制药（沈阳）科技发展有限公司 一种左卡尼汀薄膜衣片及其制备方法
CN105695398A (zh) * 2016-04-25 2016-06-22 广西大学 含o-乙酰基-l-肉碱盐酸盐的水牛卵母细胞体外成熟液及培养方法
JP7366612B2 (ja) * 2019-07-09 2023-10-23 東和薬品株式会社 レボカルニチンを含有する錠剤
MX2022012693A (es) * 2020-05-15 2022-11-07 Alfasigma Spa Composicion que comprende metilfolato.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2921852A1 (de) * 1979-05-29 1980-12-11 Fresenius Chem Pharm Ind Lipide senkendes mittel
IT1119853B (it) * 1979-09-21 1986-03-10 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente l-carnitina per il trattamento delle dislipidemie ed iperlipo proteinemie
JPS59222412A (ja) * 1983-06-01 1984-12-14 Earth Chem Corp Ltd 心臓疾患治療薬
EP0150688B1 (en) * 1983-12-28 1987-04-22 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same
IT1181682B (it) * 1985-06-11 1987-09-30 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico del parkinsonismo idiopatico o indotto
IT1190370B (it) * 1985-06-19 1988-02-16 Zambon Spa Composizione farmaceutica solida per uso orale
JPH03120211A (ja) * 1989-10-04 1991-05-22 Earth Chem Corp Ltd 粒状カルニチン製剤
US5073376A (en) * 1989-12-22 1991-12-17 Lonza Ltd. Preparations containing l-carnitine
JPH0656659A (ja) * 1992-06-10 1994-03-01 Natl Sci Council 直接打錠できる薬学組成物及びその錠剤の製造法
EP0681839A3 (en) * 1994-05-12 1997-11-12 Hirohiko Kuratsune A pharmaceutical preparation comprising an acylcarnitine
JPH0812569A (ja) * 1994-06-24 1996-01-16 Takeda Chem Ind Ltd 塩化カルニチン吸着固形物
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
JP3120211B2 (ja) 1996-05-14 2000-12-25 スガツネ工業株式会社 オーバーヘッドドア開閉用ダンパー
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
DE19629753A1 (de) * 1996-07-23 1998-01-29 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
IT1291126B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Composizioni solide atte alla somministrazione orale comprendenti sali non igroscopici della l-carnitina e delle alcanoil l-carnitine
IT1291133B1 (it) * 1997-04-07 1998-12-29 Sigma Tau Ind Farmaceuti Composizioni solide atte alla somministrazione orale comprendenti l-carnitina e alcanoil l-carnitine magnesio tartrato
IT1290600B1 (it) * 1997-04-30 1998-12-10 Sigma Tau Ind Farmaceuti Composizioni solide atte alla somministrazione orale comprendenti l-carnitina e alcanoil l-carnitine magnesio fumarato

Also Published As

Publication number Publication date
JP2001097353A (ja) 2001-04-10
ATE238784T1 (de) 2003-05-15
KR100729848B1 (ko) 2007-06-19
JP4637367B2 (ja) 2011-02-23
CZ20013078A3 (cs) 2002-02-13
PL350908A1 (en) 2003-02-10
US20020025984A1 (en) 2002-02-28
ITRM990189A1 (it) 2000-09-26
IL144957A0 (en) 2002-06-30
AU780413B2 (en) 2005-03-17
KR20010114227A (ko) 2001-12-31
WO2000057873A3 (en) 2001-04-19
CN1158072C (zh) 2004-07-21
WO2000057873A2 (en) 2000-10-05
US6485741B2 (en) 2002-11-26
CN1345235A (zh) 2002-04-17
DE60002454D1 (de) 2003-06-05
ES2197867T3 (es) 2004-01-16
EP1171111B1 (en) 2003-05-02
JP2002540153A (ja) 2002-11-26
PL207961B1 (pl) 2011-02-28
IL144957A (en) 2006-08-01
CA2363038A1 (en) 2000-10-05
DE60002454T2 (de) 2004-03-18
PT1171111E (pt) 2003-09-30
SK285565B6 (sk) 2007-03-01
CA2363038C (en) 2008-10-14
CZ301266B6 (cs) 2009-12-23
HUP0200465A2 (en) 2002-06-29
SK11592001A3 (sk) 2001-12-03
DK1171111T3 (da) 2003-08-25
IT1305308B1 (it) 2001-05-04
AU3834400A (en) 2000-10-16
HU228588B1 (en) 2013-04-29
EP1171111A2 (en) 2002-01-16

Similar Documents

Publication Publication Date Title
ATE396712T1 (de) Pharmazeutische zubereitung zur modifizierten freisetzung
SG164281A1 (en) Controlled release preparation
CO5590898A2 (es) Formas de dosificacion que comprenden un inhibidor de la ptec y un inhibidor de la hmg-coa-reductasa
AU2003274071A1 (en) Dosage form that is safeguarded from abuse
YU53101A (sh) Tableta sa produženim oslobađanjem gliklazida posle oralne primene
ES2091142T3 (es) Amilosa reticulada como aglomerante/disgregante en comprimidos.
TR200102802T2 (tr) Tabletlerin direk kompresyonla üretiminde, yüksek L-karnitin-alkanoil L-karnitinli granülat
NO813826L (no) Smertenedbrytende legemiddel-presslegemer
NO865195L (no) FremgangsmŸte for fremstilling av et retardpreparat av ibuprofen.
MXPA05008153A (es) Sistema de encapsulacion de material.
WO2004024128A3 (en) Modified release ketoprofen dosage form
WO2004078108A3 (fr) Comprime de fenofibrate et procede de fabrication
FI965214A0 (fi) Fusidihappotablettien valmistus
ATE260887T1 (de) Kompaktes 2,2-dibrom-3-nitrilo-propionamid
CA2532714A1 (en) Oral sustained-release tablet comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide
WO2002024227A1 (en) Tumor cell proliferation inhibitors
CA2406592A1 (en) Method of preparing pharmaceutical dosage forms containing multiple active ingredients